EUVIMEDOpdag EUVIMED
Open access

Design of negative‐regulating proteins of Rheb/ mTORC1 with much‐reduced sizes of the tuberous sclerosis protein complex

Wencheng Fu iD, Geng Wu

Protein Science · 2023

DOI: 10.1002/pro.4731 ↗

At a glance

Journal article in Protein Science, 2023. Written by Wencheng Fu and 1 co-authors. Institution: State Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, the Joint International Research Laboratory of Metabolic & Dev…. Major MEDLINE topics: Mechanistic Target of Rapamycin Complex 1, Neuropeptides, Tuberous Sclerosis, Tuberous Sclerosis Complex 2 Protein. Cited 6 times so far (Crossref); 36 references. The full text is freely available in PubMed Central. Funded by: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The mTORC1 signaling pathway regulates cell growth and metabolism in a variety of organisms from yeast to human, and inhibition of the mTORC1 pathway has the prospect to treat cancer or achieve longevity. The tuberous sclerosis protein complex (TSCC) is a master negative regulator of the mTORC1 signaling pathway through hydrolyzing the GTP loaded on the small GTPase Rheb, which is a key activator of mTOR. However, the large size (~700 kDa) and complex structural organization of TSCC render it vulnerable to degradation and inactivation, thus limiting its potential application. In this work, based on thorough analysis and understanding of the structural mechanism of how the stabilization domain of TSC2 secures the association of TSC2‐GAP with Rheb and thus enhances its GAP activity, we designed two proteins, namely SSG‐MTM (short stabilization domain and GAP domain‐membrane targeting motif) and SSG‐TSC1N, which were able to function like TSCC to negatively regulate Rheb and mTORC1, but with much‐reduced sizes (~1/15 and ~ 1/9 of the size of TSCC, respectively). Biochemical and cell biological assays demonstrated that these designed proteins indeed could promote the GTPase activity of Rheb to hydrolyze GTP, inhibit the kinase activity of mTORC1, and prevent mTORC1 from down‐regulating catabolism and autophagy.

Subjects

MeSH terms (MEDLINE)

Mechanistic Target of Rapamycin Complex 1NeuropeptidesTuberous SclerosisTuberous Sclerosis Complex 2 ProteinHumansGuanosine TriphosphateMultiprotein ComplexesRas Homolog Enriched in Brain ProteinTumor Suppressor Proteins

Author keywords

RhebSSG-MTMSSG-TSC1NTSC2-GAPmTORC1protein engineeringtuberous sclerosis protein complex

Substances

Guanosine TriphosphateMechanistic Target of Rapamycin Complex 1Multiprotein ComplexesNeuropeptidesRas Homolog Enriched in Brain ProteinTuberous Sclerosis Complex 2 ProteinTumor Suppressor Proteins

Authors and institutions

  • State Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, the Joint International Research Laboratory of Metabolic & Developmental Sciences MOE, Shanghai Jiao Tong University, Shanghai, Chin…

ORCID profiles: Wencheng Fu

Funding

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Cite

APA

Fu, W., & Wu, G. (2023). Design of negative‐regulating proteins of Rheb/ mTORC1 with much‐reduced sizes of the tuberous sclerosis protein complex. Protein Science. https://doi.org/10.1002/pro.4731

Vancouver

Fu W, Wu G. Design of negative‐regulating proteins of Rheb/ mTORC1 with much‐reduced sizes of the tuberous sclerosis protein complex. Protein Science. 2023. doi:10.1002/pro.4731

BibTeX
@article{Fu2023,
  author = {Fu, Wencheng and Wu, Geng},
  title = {Design of negative‐regulating proteins of Rheb/ mTORC1 with much‐reduced sizes of the tuberous sclerosis protein complex},
  journal = {Protein Science},
  year = {2023},
  doi = {10.1002/pro.4731}
}
Start for free →